Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Circulation

• Publication date

  2006-06-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.106.625467PMID 16735673PMCID PMC4105979
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic Banding

  2005cited by this paper
• Genome-Wide Screening for Target Regions of Histone Deacetylases in Cardiomyocytes

  2005cited by this paper
• Toward transcriptional therapies for the failing heart: chemical screens to modulate genes.

  2005cited by this paper
• Deactylase Inhibitors Disrupt Cellular Complexes Containing Protein Phosphatases and Deacetylases*

  2004cited by this paper
• Cardiac histone acetylation--therapeutic opportunities abound.

  2004cited by this paper
• Hypertrophy of the heart: a new therapeutic target?

  2004cited by this paper
• Beta2-microglobulin knockout mice treated with anti-asialoGM1 exhibit improved hemodynamics and cardiac contractile function during acute intra-abdominal sepsis.

  2004cited by this paper
• Histone deacetylase inhibitors: Understanding a new wave of anticancer agents

  2004cited by this paper
• Silent Information Regulator 2&agr;, a Longevity Factor and Class III Histone Deacetylase, Is an Essential Endogenous Apoptosis Inhibitor in Cardiac Myocytes

  2004cited by this paper
• β2-Microglobulin knockout mice treated with anti-asialoGM1 exhibit improved hemodynamics and cardiac contractile function during acute intra-abdominal sepsis

  2004cited by this paper
• The Transcriptional Co-activators CREB-binding Protein (CBP) and p300 Play a Critical Role in Cardiac Hypertrophy That Is Dependent on Their Histone Acetyltransferase Activity*

  2003cited by this paper
• Dose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors*

  2003cited by this paper
• Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2

  2003cited by this paper
• Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.

  2003cited by this paper
• Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts.

  2002cited by this paper
• HDAC6 is a microtubule-associated deacetylase

  2002cited by this paper
• Small Amounts of &agr;-Myosin Heavy Chain Isoform Expression Significantly Increase Power Output of Rat Cardiac Myocyte Fragments

  2002cited by this paper
• Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.

  2002cited by this paper
• Trichostatin A, a Histone Deacetylase Inhibitor, Suppresses Collagen Synthesis and Prevents TGF-β1-Induced Fibrogenesis in Skin Fibroblasts

  2002cited by this paper
• Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

  2002cited by this paper
• Targeted Inhibition of Calcineurin in Pressure-overload Cardiac Hypertrophy

  2002cited by this paper
• MEF2: a calcium-dependent regulator of cell division, differentiation and death.

  2002cited by this paper
• Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo

  2002cited by this paper
• Concentric versus eccentric remodeling.

  2002cited by this paper
• Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo.

  2002cited by this paper
• The Neuron-Restrictive Silencer Element–Neuron-Restrictive Silencer Factor System Regulates Basal and Endothelin 1-Inducible Atrial Natriuretic Peptide Gene Expression in Ventricular Myocytes

  2001cited by this paper
• Translating the Histone Code

  2001cited by this paper
• Cardiac hypertrophy is not a required compensatory response to short-term pressure overload.

  2000cited by this paper
• Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases.

  2000cited by this paper
• Acetylation: a regulatory modification to rival phosphorylation?

  2000cited by this paper
• Myosin heavy chain isoform expression in the failing and nonfailing human heart.

  2000cited by this paper
• Global histone acetylation and deacetylation in yeast

  2000cited by this paper
• Histone deacetylases: complex transducers of nuclear signals.

  1999cited by this paper
• Myosin heavy chain gene expression in human heart failure.

  1997cited by this paper
• Erratum: Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy (Proc. Natl. Acad. Sci. USA (September 1991) 88 (8277-8281))

  1991cited by this paper
• Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy

  1991cited by this paper
• Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements.

  1985cited by this paper

• Expression and Regulation of Npr1 Gene Coding for Natriuretic Peptide Receptor-A in Hypertrophied Heart: Mechanisms and Therapeutic Implications

  2026cites this paper
• LncRNA ZEB1-AS1: A New Player in Epigenetic Control of Cardiac Hypertrophy.

  2026cites this paper
• Enzyme-independent functions of HDAC3 in the adult heart

  2025cites this paper
• Role of Perturbations of Epigenetic Processes in Cardiac Hypertrophy and Fibrotic Scarring.

  2025cites this paper
• Transcription Factor Yin-Yang 1 governs cardiac metabolic reprogramming in response to exercise or pathological stress.

  2025cites this paper
• Downregulation of HDAC2 attenuates ventricular arrhythmias in a mouse model of cardiac hypertrophy through upregulation of KCHIP2 expression.

  2025cites this paper
• Givinostat inhibits in vitro differentiation of cardiac fibroadipogenic precursors from a mouse model of arrhythmogenic cardiomyopathy.

  2025cites this paper
• Epigenetic Mechanisms in Heart Diseases

  2025cites this paper
• Gene editing for inherited cardiac conditions: A new frontier in cardiology.

  2025cites this paper
• Histone deacetylases in myocardial infarction: Orchestrating programmed cell death pathways and emerging therapeutic opportunities.

  2025cites this paper
• LncRNA ZEB1-AS1: A New Player in Epigenetic Control of Cardiac Hypertrophy

  2025cites this paper
• VCAM-1/Ezrin axis antagonizes myocardial damage in ischemia-reperfusion injury.

  2025cites this paper
• Unraveling the metabolic‒epigenetic nexus: a new frontier in cardiovascular disease treatment

  2025cites this paper
• Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment

  2025cites this paper
• Acetylation in Cardiac Aging: Molecular Mechanism and Therapeutic Approaches.

  2025cites this paper
• Histone Deacetylase Inhibitors as a Promising Treatment Against Myocardial Infarction: A Systematic Review

  2024cites this paper
• The MYPT2-regulated striated muscle-specific myosin light chain phosphatase limits cardiac myosin phosphorylation in vivo

  2024cites this paper
• LMK235 ameliorates inflammation and fibrosis after myocardial infarction by inhibiting LSD1-related pathway

  2024cites this paper
• An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

  2024cites this paper
• Proteomics of the heart

  2024cites this paper
• Targeting histone deacetylase in cardiac diseases

  2024cites this paper
• OGT mediated HDAC5 O-GlcNAcylation promotes osteogenesis by regulating the homeostasis of epigenetic modifications and proteolysis

  2024cites this paper
• The Role of Epigenetics in Myocardial Infarction: Mechanism and Therapeutic Potential

  2024cites this paper
• Epigenetics in Heart Failure

  2024cites this paper
• A novel histone deacetylase inhibitor Se-SAHA attenuates isoproterenol-induced heart failure via antioxidative stress and autophagy inhibition.

  2024cites this paper
• Transient cerebral ischaemia alters mesenteric arteries in hypertensive rats: Limited reversal despite suberoylanilide hydroxamic acid cerebroprotection.

  2024cites this paper
• Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications

  2024cites this paper
• HBI‐8000 improves heart failure with preserved ejection fraction via the TGF‐β1/MAPK signalling pathway

  2024cites this paper
• Enzyme-independent functions of HDAC3 in the adult heart

  2024cites this paper
• Histone deacetylase 6 as a novel promising target to treat cardiovascular disease

  2024cites this paper
• Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure

  2023cites this paper
• Cardiac Fibrosis in heart failure: Focus on non-invasive diagnosis and emerging therapeutic strategies.

  2023cites this paper
• Epigenetic Modifiers as Game Changers for Healthy Aging

  2023cites this paper
• Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction

  2023cites this paper
• Targeting histone deacetylases for heart diseases.

  2023cites this paper
• The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?

  2023cites this paper
• Ketones and the Heart: Metabolic Principles and Therapeutic Implications

  2023cites this paper
• Epigenetics in cardiovascular health and disease.

  2023cites this paper
• SGLT2 Inhibitors and Ketone Metabolism in Heart Failure

  2022cites this paper
• Short-Chain Fatty Acids in Gut–Heart Axis: Their Role in the Pathology of Heart Failure

  2022cites this paper
• Epi-Drugs in Heart Failure

  2022influential citation
• Critical Functions of Histone Deacetylases (HDACs) in Modulating Inflammation Associated with Cardiovascular Diseases

  2022cites this paper
• Association of Valproic Acid Use With Post-Myocardial Infarction Heart Failure Development: A Meta-Analysis of Two Retrospective Case–Control Studies

  2022cites this paper
• Emerging epigenetic therapies of cardiac fibrosis and remodeling in heart failure: from basic mechanisms to early clinical development.

  2022cites this paper
• Stachydrine hydrochloride ameliorates cardiac hypertrophy through CaMKII/HDAC4/MEF2C signal pathway.

  2022cites this paper
• NRSF/REST-Mediated Epigenomic Regulation in the Heart: Transcriptional Control of Natriuretic Peptides and Beyond

  2022cites this paper
• The impacts of vorinostat on NADPH oxidase and mitochondrial biogenesis gene expression in heart of animal model of depression.

  2022cites this paper
• Altered Cellular Protein Quality Control System Modulates Cardiomyocyte Function in Volume Overload-Induced Hypertrophy

  2022cites this paper
• Emerging therapeutic targets for cardiac hypertrophy

  2022cites this paper
• Hdac8 Inhibitor Alleviates Transverse Aortic Constriction-Induced Heart Failure in Mice by Downregulating Ace1

  2022cites this paper
• Human iPSC-Cardiomyocytes as an Experimental Model to Study Epigenetic Modifiers of Electrophysiology

  2022influential citation
• Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials

  2022cites this paper
• Autophagy in striated muscle diseases

  2022cites this paper
• Systemic study of selected HDAC inhibitors in cardiac complications associated with cancer cachexia.

  2021cites this paper
• Novel Therapeutic Targets for the Treatment of Right Ventricular Remodeling: Insights from the Pulmonary Artery Banding Model

  2021cites this paper
• Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure

  2021cites this paper
• Cardiovascular disorders and epigenetics

  2021cites this paper
• Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease

  2021cites this paper
• Histone modifications in cardiovascular disease initiation and progression

  2021cites this paper
• HDAC Inhibition in the Heart: Erasing Hidden Fibrosis.

  2021cites this paper
• Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy

  2021cites this paper
• Histone deacetylase 2-dependent ventricular electrical remodeling in a porcine model of early heart failure.

  2021cites this paper
• HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling

  2021cites this paper
• Protein acetylation in cardiac aging.

  2021cites this paper
• Activation of Autophagic Flux Blunts Cardiac Ischemia/Reperfusion Injury

  2021cites this paper
• The Anti-Inflammatory Properties of Phytochemicals and Their Effects on Epigenetic Mechanisms Involved in TLR4/NF-κB-Mediated Inflammation

  2021cites this paper
• Metabolic Aspects of Anthracycline Cardiotoxicity

  2021cites this paper
• Epigenetics-based therapeutics for myocardial fibrosis.

  2021cites this paper
• Epigenetic regulation of cardiac electrophysiology in atrial fibrillation: HDAC2 determines action potential duration and suppresses NRSF in cardiomyocytes

  2021cites this paper
• BET Protein-Mediated Transcriptional Regulation in Heart Failure

  2021cites this paper
• Cellular and molecular pathobiology of heart failure with preserved ejection fraction

  2021cites this paper
• Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC Focus Seminar.

  2021cites this paper
• Protein lysine acetylation and its role in different human pathologies: a proteomic approach

  2021cites this paper
• Histone modification as a potential preventative and therapeutic approach for cardiovascular disease

  2020cites this paper
• CaMKII exacerbates heart failure progression by activating class I HDACs.

  2020cites this paper
• Identification and characterization of small molecule modulators of cardiac hypertrophy

  2020cites this paper
• Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening

  2020cites this paper
• Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs. Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart.

  2020cites this paper
• Overexpression of peptidase inhibitor 16 attenuates angiotensin II–induced cardiac fibrosis via regulating HDAC1 of cardiac fibroblasts

  2020cites this paper
• A Case for Adaptive Cardiac Hypertrophic Remodeling Is CITED.

  2020cites this paper
• Histone modifications in diseases

  2020cites this paper
• FoxO1–Dio2 signaling axis governs cardiomyocyte thyroid hormone metabolism and hypertrophic growth

  2020cites this paper
• HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction

  2020cites this paper
• Dietary natural products as epigenetic modifiers in aging-associated inflammation and disease.

  2020cites this paper
• Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy.

  2020influential citation
• Epigenetic Signatures of Human Myocardium and Brown Adipose Tissue Revealed with Simultaneous Positron Emission Tomography and Magnetic Resonance of Class I Histone Deacetylases

  2020cites this paper
• MicroRNA-489 suppresses isoproterenol-induced cardiac fibrosis by downregulating histone deacetylase 2

  2020cites this paper
• Therapeutic effects of histone deacetylase inhibitors on heart disease

  2020cites this paper
• HDAC5 inhibition reduces angiotensin II-induced vascular contraction, hypertrophy, and oxidative stress in a mouse model.

  2020cites this paper
• High Phosphate Diet Induces Exercise Intolerance and Impairs Fatty Acid Metabolism in Mice

  2019cites this paper
• Proteomic insights into lysine acetylation and the implications for medical research

  2019cites this paper
• Nitrosative stress drives heart failure with preserved ejection fraction

  2019cites this paper
• HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases

  2019cites this paper
• Ca2+/calmodulin-dependent protein kinase II is essential in hyperacute pressure overload.

  2019cites this paper
• Heart failure with preserved ejection fraction: present status and future directions

  2019cites this paper
• Epigenetics in Cardiac Hypertrophy and Heart Failure

  2019cites this paper
• Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association.

  2019cites this paper
• Novel Insight Into the Epigenetic and Post-transcriptional Control of Cardiac Gene Expression by Thyroid Hormone

  2019cites this paper
• Dietary restriction in the epigenomic regulation of cardiovascular diseases

  2019cites this paper
• Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy

  2019cites this paper